Harnessing autophagy for cell fate control gene therapy

Autophagy

Volumn 9, Issue 7, 2013, Pages 1069-1079

  Felizardo, Tania C ^a   Foley, Jason ^a   Steed, Kevin ^a   Dropulic, Boro ^b   Amarnath, Shoba ^a   Medin, Jeffrey A ^c   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Lentigen Corporation   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Autophagy; Cell fate control; DTYMK TMPK; Rapamycin; Suicide gene

Indexed keywords

CD19 ANTIBODY; HYBRID PROTEIN; LENTIVIRUS VECTOR; RAPAMYCIN; ZIDOVUDINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOPHAGY; CELL DEATH; CELL FATE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; EX VIVO STUDY; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOGENETICS; IN VITRO STUDY; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE; T RAPA CELL; TRANSGENE; XENOGRAFT;

AUTOPHAGY; CELL-FATE CONTROL; DTYMK/TMPK; RAPAMYCIN; SUICIDE GENE;

ADENINE; ANIMALS; ANTIGENS, CD19; APOPTOSIS; AUTOPHAGY; CD4-POSITIVE T-LYMPHOCYTES; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; GENETIC THERAPY; HUMANS; LENTIVIRUS; MICE; NUCLEOSIDE-PHOSPHATE KINASE; PHENOTYPE; SIROLIMUS; TRANSDUCTION, GENETIC; TRANSGENES; ZIDOVUDINE;

EID: 84880885997     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.24639     Document Type: Article

References (41)

1. Amarnath S, Flomerfelt FA, Costanzo CM, Foley JE, Mariotti J, Konecki DM, et al. Rapamycin generates anti-Apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy 2010; 6:523-41; PMID:20404486; http://dx.doi.org/10.4161/auto.6.4.11811
2. Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M, et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-Tumor effects via an IL-4-dependent mechanism. J Immunol 2005; 175:5732-43; PMID:16237064
3. Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, et al. Ex vivo rapamycin generates apoptosisresistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol 2008; 180:89-105; PMID:18097008
4. Mossoba MEMJ, Yan XY, Gangopadhyay A, Winterton M, Sabatino M, Khuu H, Fowler DH. T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells. ASH Annual Meeting, 2010:352.
5. Amarnath S, Fowler DH. Harnessing autophagy for adoptive T-cell therapy. Immunotherapy 2012; 4:1-4; PMID:22149992; http://dx.doi.org/10.2217/imt.11.144
6. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID:16946036; http://dx.doi.org/10.1126/ science.1129003
7. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67:3898-903; PMID:17440104; http://dx.doi.org/10.1158/0008-5472.CAN-06-3986
8. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17:1453-64; PMID:19384291; http://dx.doi.org/10.1038/mt.2009.83
9. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009; 106:3360-5; PMID:19211796; http://dx.doi.org/10.1073/pnas.0813101106
10. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
11. Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, et al. T-cell receptor gene therapy targeting melanoma-Associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/?cnull mice. Cancer Sci 2012; 103:17-25; PMID:21951605; http://dx.doi.org/10.1111/j.1349-7006.2011.02111.x
12. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091-101; PMID:21105791; http://dx.doi.org/10.1056/NEJMoa1004383
13. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276:1719-24; PMID:9180086; http://dx.doi.org/10.1126/science.276.5319.1719
14. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:913-24; PMID:17640595; http://dx.doi.org/10.1016/j.bbmt.2007.04.005
15. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-83; PMID:22047558; http://dx.doi.org/10.1056/NEJMoa1106152
16. Bolaños-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant 2007; 13:1185-91; PMID:17889355; http://dx.doi.org/10. 1016/j.bbmt.2007.06.011
17. Kline J, Subbiah S, Lazarus HM, van Besien K. Autologous graft-versus-host disease: harnessing anti-Tumor immunity through impaired selftolerance. Bone Marrow Transplant 2008; 41:505-13; PMID:18026144; http://dx.doi.org/10.1038/sj.bmt.1705931
18. Cogbill CH, Drobyski WR, Komorowski RA. Gastrointestinal pathology of autologous graft-versushost disease following hematopoietic stem cell transplantation: a clinicopathological study of 17 cases. Mod Pathol 2011; 24:117-25; PMID:20953169; http://dx.doi.org/10.1038/modpathol.2010.163
19. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007; 15:962-70; PMID:17375075; http://dx.doi.org/10.1038/mt.sj.6300122
20. Scaife M, Pacienza N, Au BC, Wang JC, Devine S, Scheid E, et al. Engineered human Tmpk fused with truncated cell-surface markers: versatile cellfate control safety cassettes. Gene Ther 2013; 20:24-34; PMID:22241175; http://dx.doi.org/10.1038/gt.2011.210
21. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3:542-5; PMID:17611390
22. Bjørkøy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol 2009; 452:181-97; PMID:19200883; http://dx.doi.org/10.1016/S0076-6879(08)03612-4
23. Rodriguez-Enriquez S, Kim I, Currin RT, Lemasters JJ. Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepatocytes. Autophagy 2006; 2:39-46; PMID:16874071
24. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 2007; 462:245-53; PMID:17475204; http://dx.doi.org/10.1016/j.abb.2007.03.034
25. Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A 1982; 79:1889-92; PMID:6952238; http://dx.doi.org/10.1073/pnas. 79.6.1889
26. Mourtada-Maarabouni M, Hasan AM, Farzaneh F, Williams GT. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-Arrest-specific transcript 5 (GAS5). Mol Pharmacol 2010; 78:19-28; PMID:20421347; http://dx.doi.org/10.1124/mol.110.064055
27. Lin JT, Lineberry NB, Kattah MG, Su LL, Utz PJ, Fathman CG, et al. Naive CD4 t cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. J Immunol 2009; 182:5919-28; PMID:19414743; http://dx.doi.org/10.4049/jimmunol. 0803986
28. Khan M. Immunopharmacology. Springer Science+Business Media, LLC, 2008.
29. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011; 3:ra120; PMID:22133721; http://dx.doi.org/10.1126/scitranslmed.3003130
30. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107:2294-302; PMID:16282341; http://dx.doi.org/10.1182/blood-2005-08-3503
31. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3'-Azido-3'-deoxythymidine and selective interaction of the 5'-Triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986; 83:8333-7; PMID:2430286; http://dx.doi.org/10. 1073/pnas.83.21.8333
32. Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 1998; 273:3963-6; PMID:9461583; http://dx.doi.org/10.1074/jbc.273.7.3963
33. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84; PMID:16469695; http://dx.doi.org/10.1016/j. cell.2006.01.016
34. Díaz-Troya S, Pérez-Pérez ME, Florencio FJ, Crespo JL. The role of TOR in autophagy regulation from yeast to plants and mammals. Autophagy 2008; 4:851-65; PMID:18670193
35. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 358:70-3; PMID:1614535; http://dx.doi.org/10.1038/358070a0
36. Brennan P, Babbage JW, Thomas G, Cantrell D. p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol Cell Biol 1999; 19:4729-38; PMID:10373522
37. Korin YD, Zack JA. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 1998; 72:3161-8; PMID:9525642
38. Unutmaz D, KewalRamani VN, Marmon S, Littman DR. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 1999; 189:1735-46; PMID:10359577; http://dx.doi.org/10.1084/jem.189.11.1735
39. Slavik JM, Lim DG, Burakoff SJ, Hafler DA. Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bclxL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. J Biol Chem 2004; 279:910-9; PMID:14573608; http://dx.doi.org/10.1074/ jbc.M209733200
40. Fowler DHMM, Schuver BB, Layton P, Hakin FT, Kurlander R, et al. Adoptive transfer of Treg-depleted donor Th1 and Th2 cells safely accelerates alloengraftment after low-intensity chemotherapy. Blood (ASH Annual Meeting Abstracts) 2010:521.
41. Felizardo TC, Wang JC, McGray RA, Evelegh C, Spaner DE, Fowler DH, et al. Differential immune responses mediated by adenovirus-And lentivirustransduced DCs in a HER-2/neu overexpressing tumor model. Gene Ther 2011; 18:986-95; PMID:21490686; http://dx.doi.org/10.1038/gt.2011.53